Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 5 (2008), Issue 3 (March)

1. Imatinib mesylate (IM)-induced growth inhibition is associated with production of spliced osteocalcin-mRNA in cell lines.
   Leuk Res, 32(3): 437-43. [Abstract] [Full-text]
2. Rectal gastrointestinal stromal tumors associated with a novel germline KIT mutation.
   Int J Cancer, 122(9): 2160-4. [Abstract] [Full-text]
3. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
   Histopathology. [Abstract] [Full-text]
4. Characterization of neuroprogenitor cells expressing the PDGF beta-receptor within the subventricular zone of postnatal mice.
   Mol Cell Neurosci, 37(3): 507-18. [Abstract] [Full-text]
5. A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates.
   Anal Biochem, 375(1): 18-26. [Abstract] [Full-text]
6. Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis.
   Int J Hematol, 87(2): 167-71. [Abstract] [Full-text]
7. Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine.
   Ophthalmology, 115(3): 483-7. [Abstract] [Full-text]
8. Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation.
   Leuk Res, 32(5): 709-16. [Abstract] [Full-text]
9. Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.
   Am J Hematol, 83(4): 296-302. [Abstract] [Full-text]
10. KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia.
    Leuk Res, 32(5): 761-70. [Abstract] [Full-text]
11. Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070.
    Leukemia, 22(3): 572-7. [Abstract] [Full-text]
12. Subcellular distribution of p210(BCR-ABL) in CML cell lines and primary CD34+ CML cells.
    Leukemia, 22(3): 559-71. [Abstract] [Full-text]
13. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: Lessons from the phase 3 trials.
    Eur J Cancer, 44(4): 501-9. [Abstract] [Full-text]
14. Long-term follow-up in 54 surgically treated patients with gastrointestinal stromal tumours.
    Langenbecks Arch Surg. [Abstract] [Full-text]
15. Dacarbazine-Doxorubicin therapy ameliorated an extremely aggressive mesenteric desmoid tumor associated with familial adenomatous polyposis: report of a case.
    Jpn J Clin Oncol, 38(3): 222-6. [Abstract] [Full-text]
16. Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.
    Cancer Lett, 262(2): 232-8. [Abstract] [Full-text]
17. Sudden extramedullary T-lymphoblastic blast crisis in chronic myelogenous leukemia: a nonrandom event associated with imatinib?
    Am J Clin Pathol, 129(4): 639-48. [Abstract] [Full-text]
18. Chemotherapeutic agents and the skin: An update.
    J Am Acad Dermatol, 58(4): 545-70. [Abstract] [Full-text]
19. Modeling imatinib-treated chronic myelogenous leukemia: reducing the complexity of agent-based models.
    Bull Math Biol, 70(3): 728-44. [Abstract] [Full-text]
20. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer.
    Clin Cancer Res, 14(6): 1599-602. [Abstract] [Full-text]
21. Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib?
    J Cancer Res Clin Oncol, 134(5): 625-30. [Abstract] [Full-text]
22. Molecular Pathobiology of Gastrointestinal Stromal Sarcomas.
    Annu Rev Pathol, 3: 557-586. [Abstract] [Full-text]
23. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.
    Br J Haematol, 141(2): 200-4. [Abstract] [Full-text]
24. Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.
    Leuk Res. [Abstract] [Full-text]
25. BCR/ABL expression of myeloid progenitors increases beta1-integrin mediated adhesion to stromal cells.
    J Mol Biol, 377(4): 1082-93. [Abstract] [Full-text]
26. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
    Leuk Res, 32(6): 855-64. [Abstract] [Full-text]
27. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.
    Leuk Res, 32(6): 980-3. [Abstract] [Full-text]
28. An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation.
    Leuk Res, 32(6): 936-43. [Abstract] [Full-text]
29. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
    Leuk Res, 32(6): 962-71. [Abstract] [Full-text]
30. Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms.
    Drug Metab Dispos, 36(4): 780-95. [Abstract] [Full-text]
31. Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway.
    J Biol Chem, 283(13): 8601-10. [Abstract] [Full-text]
32. Irreversible sensorineural hearing loss due to Imatinib.
    Leuk Res, 32(6): 991-2. [Abstract] [Full-text]
33. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma.
    Neuro Oncol. [Abstract] [Full-text]
34. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
    Blood, 111(7): 3723-34. [Abstract] [Full-text]
35. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
    Blood, 111(7): 3821-9. [Abstract] [Full-text]
36. Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis.
    Blood, 111(7): 3760-9. [Abstract] [Full-text]
37. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.
    Blood, 111(7): 3735-41. [Abstract] [Full-text]
38. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases.
    Mod Pathol, 21(4): 476-84. [Abstract] [Full-text]
39. Targeted therapies for patients with germ cell tumors.
    Expert Opin Investig Drugs, 17(4): 511-22. [Abstract] [Full-text]
40. Chronic myeloid leukemia following the treatment of rectal adenocarcinoma.
    Med Oncol. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.